Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Adaptive Biotechnologies Corporation - Common Stock (NQ:ADPT)

17.59 +1.60 (+10.01%)
Streaming Delayed Price Updated: 10:33 AM EDT, Jun 4, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Adaptive Biotechnologies Corporation - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 Next >
News headline image
Adaptive Biotechnologies Highlights clonoSEQ Growth, 2026 Cash Flow Goal at Conference ↗
Adaptive Biotechnologies (NASDAQ:ADPT) Chief Executive Officer and Co-Founder Chad Robins said the company is focused on expanding its minimal residual disease testing business while pursuing targeted... 
Via MarketBeat
News headline image
At ASCO and EHA 2026, New Data Reinforce the Pivotal Role of clonoSEQ® MRD Testing Across Hematology Clinical Practice and Research
Over 30 scientific presentations leverage clonoSEQ MRD testing to assess novel therapies and support MRD-guided patient care across blood cancers 
From Adaptive Biotechnologies
Via GlobeNewswire
News headline image
Harvest Investment Services Dumps 356,000 Adaptive Biotechnologies (ADPT) Shares Worth $5.7 Million ↗
Adaptive Biotechnologies develops immune-driven diagnostics and research tools for the life sciences and healthcare sectors. 
Via The Motley Fool
Topics Regulatory Compliance
Adaptive Biotechnologies (NASDAQ:ADPT) Surges 6% on Q1 Beat and Raised MRD Guidance ↗
Via Chartmill
Adaptive Biotechnologies (NASDAQ:ADPT) Reports Strong Q4 Revenue Beat and Path to Profitability ↗
Via Chartmill
News headline image
Adaptive Biotechnologies to Participate in Upcoming Investor Conferences
From Adaptive Biotechnologies
Via GlobeNewswire
News headline image
Adaptive (ADPT) Q1 2026 Earnings Transcript ↗
Adaptive (ADPT) Q1 2026 Earnings Transcript 
Via The Motley Fool
Get insights into the top gainers and losers of Tuesday's after-hours session. ↗
Via Chartmill
News headline image
Adaptive Biotechnologies Reports First Quarter 2026 Financial Results
From Adaptive Biotechnologies
Via GlobeNewswire
News headline image
Adaptive Biotechnologies' Chief Operating Officer Sold Over 19,000 Company Shares. Here's What That Means for Investors. ↗
This immune diagnostics innovator reported a notable insider sale as it advances platforms for disease detection and monitoring. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Adaptive Biotechnologies' COO Is Running a Systematic Sell Program — Here's What It Means ↗
This immune diagnostics firm reported a notable insider sale as it expands its clinical portfolio and strategic partnerships. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Should You Sell Adaptive Biotechnologies (ADPT) After Its President and COO Sold 57,000 Shares? ↗
This Seattle-based biotech, known for its immune medicine platform, reported a notable insider sale amid ongoing industry partnerships. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Adaptive Biotechnologies to Report First Quarter 2026 Financial Results on May 5, 2026
From Adaptive Biotechnologies
Via GlobeNewswire
News headline image
Adaptive Biotech Insider Sells $554K as Revenue Jumps 55%, but Here's What Investors Should Focus On ↗
This immuno-driven diagnostics company, known for partnerships with Genentech and Microsoft, just reported a notable insider sale. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Adaptive Biotech's President Trimmed Her Position. But what Remains is worth a look ↗
Adaptive Biotechnologies, a leader in immune-driven diagnostics, reported a notable insider sale amid strong one-year stock gains. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Adaptive Biotech Insider Sale of 180,000 Shares Tied to Tax Event as Stock Jumps 70% in a Year ↗
Adaptive Biotechnologies, a leader in immune-driven diagnostics, saw a notable insider sale amid ongoing innovation in disease monitoring. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Adaptive Biotechnologies Insider Sells $1 Million in Stock After a Doubling in Share Price ↗
Adaptive Biotechnologies, a leader in immune-driven diagnostics, reported a notable insider sale after a strong one-year stock performance. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Adaptive Biotech (ADPT) Earnings Call Transcript ↗
Adaptive Biotech (ADPT) Earnings Call Transcript 
Via The Motley Fool
Topics Earnings
News headline image
Adaptive Biotechnologies Reports Fourth Quarter and Full Year 2025 Financial Results
From Adaptive Biotechnologies
Via GlobeNewswire
News headline image
Adaptive Biotechnologies to Participate in Upcoming Investor Conferences
From Adaptive Biotechnologies
Via GlobeNewswire
News headline image
Adaptive Biotechnologies to Report Fourth Quarter and Full Year 2025 Financial Results on February 5, 2026
From Adaptive Biotechnologies
Via GlobeNewswire
News headline image
Adaptive Biotechnologies Surges as Preliminary 2025 Results Signal a Turning Point in MRD Commercialization
Shares of Adaptive Biotechnologies (NASDAQ: ADPT) soared on Tuesday, January 13, 2026, after the life sciences company announced preliminary fourth-quarter and full-year 2025 financial results that... 
Via MarketMinute
News headline image
Adaptive Biotechnologies Announces Preliminary Fourth Quarter and Full Year 2025 Results
Full year MRD revenue growth of 46% driven by clonoSEQ® testing volume 
From Adaptive Biotechnologies
Via GlobeNewswire
News headline image
The Year-End Biotech Chill: Adaptive Biotechnologies Braces for J.P. Morgan Crucible Amid Market Sell-Off
As the final trading days of 2025 wind down, the biotechnology sector finds itself caught in a paradoxical "bifurcated" squeeze. While the broader indices have touched record highs this year, a sharp... 
Via MarketMinute
Topics Artificial Intelligence Economy Intellectual Property
News headline image
Adaptive Biotechnologies to Present at the 44th Annual J.P. Morgan Healthcare Conference
From Adaptive Biotechnologies
Via GlobeNewswire
News headline image
Adaptive Biotechnologies Announces Two Immune Receptor Licensing Agreements with Pfizer
From Adaptive Biotechnologies
Via GlobeNewswire
News headline image
Adaptive Biotechnologies to Participate in Jefferies Fireside Chat Series on Minimal Residual Disease
From Adaptive Biotechnologies
Via GlobeNewswire
News headline image
Adaptive Biotechnologies Showcases Leadership in Hematology-Oncology MRD with New clonoSEQ® Data Driving Treatment Interventions at 2025 ASH Annual Meeting
From Adaptive Biotechnologies
Via GlobeNewswire
News headline image
Adaptive Biotechnologies Announces Nearly 90 Abstracts Featuring clonoSEQ® MRD Testing Across a Range of Blood Cancers to be Presented at the 67th ASH Annual Meeting
Record-setting presence at ASH reflects widespread recognition of clonoSEQ as a standard-of-care tool for personalizing patient care and accelerating drug development 
From Adaptive Biotechnologies
Via GlobeNewswire
News headline image
Adaptive Biotechnologies to Participate in Upcoming Investor Conferences
From Adaptive Biotechnologies
Via GlobeNewswire
< Previous 1 2 3 4 5 6 7 8 9 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.